Table 2 Open in new tab Multivariate...

Risk Group	OS^a	PFS^b	CB^c
Body composition risk group analysis
High risk: risk score = 0–1, n = 20	6.72 (2.42–16.78)	<.001	5.82 (2.00–11.61)	<.001	0.02 (0.00–0.28)	.003
Median, mo	2.7		1.9
12-month rate, %	19.7		7.5
Intermediate risk: risk score = 2–3, n = 29	2.99 (1.12–7.98)	.029	3.16 (1.41–7.06)	.005	0.11 (0.02–0.53)	.006
Median, mo	8.9		3.4
12-month rate, %	45.1		20.0
Low risk: risk score = 4, n = 20	1		1		1
Median, mo	Not reached		10.4
12-month rate	65.8		48.5
Myosteatosis analysis^d
High, n = 20	2.85 (1.48–5.46)	.002	3.09 (1.67–5.72)	<.001	0.049 (0.003–0.80)	.034
Low, n = 49	1		1		1

Risk Group	OS^a	PFS^b	CB^c
Body composition risk group analysis
High risk: risk score = 0–1, n = 20	6.72 (2.42–16.78)	<.001	5.82 (2.00–11.61)	<.001	0.02 (0.00–0.28)	.003
Median, mo	2.7		1.9
12-month rate, %	19.7		7.5
Intermediate risk: risk score = 2–3, n = 29	2.99 (1.12–7.98)	.029	3.16 (1.41–7.06)	.005	0.11 (0.02–0.53)	.006
Median, mo	8.9		3.4
12-month rate, %	45.1		20.0
Low risk: risk score = 4, n = 20	1		1		1
Median, mo	Not reached		10.4
12-month rate	65.8		48.5
Myosteatosis analysis^d
High, n = 20	2.85 (1.48–5.46)	.002	3.09 (1.67–5.72)	<.001	0.049 (0.003–0.80)	.034
Low, n = 49	1		1		1

Table 2

Multivariate analysis of association between risk groups and myosteatosis with clinical outcomes

Risk Group	OS^a		PFS^b		CB^c
Risk Group	HR (CI)	p value	HR (CI)	p value	OR (CI)	p value
Body composition risk group analysis
High risk: risk score = 0–1, n = 20	6.72 (2.42–16.78)	<.001	5.82 (2.00–11.61)	<.001	0.02 (0.00–0.28)	.003
Median, mo	2.7		1.9
12-month rate, %	19.7		7.5
Intermediate risk: risk score = 2–3, n = 29	2.99 (1.12–7.98)	.029	3.16 (1.41–7.06)	.005	0.11 (0.02–0.53)	.006
Median, mo	8.9		3.4
12-month rate, %	45.1		20.0
Low risk: risk score = 4, n = 20	1		1		1
Median, mo	Not reached		10.4
12-month rate	65.8		48.5
Myosteatosis analysis^d
High, n = 20	2.85 (1.48–5.46)	.002	3.09 (1.67–5.72)	<.001	0.049 (0.003–0.80)	.034
Low, n = 49	1		1		1

Risk Group	OS^a		PFS^b		CB^c
Risk Group	HR (CI)	p value	HR (CI)	p value	OR (CI)	p value
Body composition risk group analysis
High risk: risk score = 0–1, n = 20	6.72 (2.42–16.78)	<.001	5.82 (2.00–11.61)	<.001	0.02 (0.00–0.28)	.003
Median, mo	2.7		1.9
12-month rate, %	19.7		7.5
Intermediate risk: risk score = 2–3, n = 29	2.99 (1.12–7.98)	.029	3.16 (1.41–7.06)	.005	0.11 (0.02–0.53)	.006
Median, mo	8.9		3.4
12-month rate, %	45.1		20.0
Low risk: risk score = 4, n = 20	1		1		1
Median, mo	Not reached		10.4
12-month rate	65.8		48.5
Myosteatosis analysis^d
High, n = 20	2.85 (1.48–5.46)	.002	3.09 (1.67–5.72)	<.001	0.049 (0.003–0.80)	.034
Low, n = 49	1		1		1

^a OS controlled for Eastern Cooperative Oncology Group performance status (ECOG PS), number of prior lines of therapy, neutrophil-to-lymphocyte ratio (NLR), and liver metastasis. Number of observations in the original data set = 70. Number of observations used = 69 in multivariate analysis.

^b PFS controlled for number of prior lines of therapy, NLR, and liver metastasis.

^c CB controlled for ECOG PS, and age.

^d High versus low myosteatosis determined by optimal cut analysis.

Abbreviations: CB, clinical benefit; CI, confidence interval; HR, hazard ratio; mo, months; OR, odds ratio; OS, overall survival; PFS, progression-free survival.

This Feature Is Available To Subscribers Only